Cardiovascular risk prediction: Are we there yet?

Heart

Volumn 94, Issue 1, 2008, Pages 1-3

  Jackson, Rod ^a,b  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EDITORIAL; HUMAN; HYPERTENSION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

CARDIOVASCULAR DISEASES; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 37749020706     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.138040     Document Type: Editorial

References (19)

1. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976;37:269-82.
2. Jackson R, Lawes C, Bennett D, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.
3. Wells S, Furness S, Rafter N, et al. Integrated electronic decision support increases CVD risk assessment four fold in routine primary care practice. Eur J Cardiovasc Prev Rehab (in press).
4. Rafter N, Connor J, Hall J, et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. NZ Med J 2005;11:1676.
5. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996;124:414-21.
6. Guideline Development Team. The assessment and management of cardiovascular risk. New Zealand Guideline Group. 2003. Available at http://www.nzgg.org.nz (accessed 6 November 2007).
7. Task Force. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehab 2007;14(Suppl 2):E1-40.
8. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008;94:34-9.
9. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-8.
10. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;2:272-98.
11. Law MR, Wald NJ, Rudnicka AR. Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
12. Mangin D, Sweeney K, Heath I. Preventive health care in elderly people needs rethinking. BMJ 2007;335:285-7.
13. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007: bmj.39261.471806.55.
14. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6.
15. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
16. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease guidance type: technology appraisal. In: Excellence NIfHaC, 2006.
17. Kannel WB, McGee D, Gordon T. A General cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46-51.
18. Milne R, Gamble G, Whitlock G, et al. Discriminative ability of a Framingham Heart Study-derived risk prediction tool compared with single risk factors. NZ Med J 2003;11:662.
19. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) Study. Circulation 2002;105:310-5.